Table 1.
Subject demographics and characteristics at baseline in parent and extension studies
| Years 1–4 parent study | Years 5–8 extension study | ||
|---|---|---|---|
| All subjects (N = 412) | Denosumab (N = 319) | Denosumab (N = 200) | |
| Age, years | 62.5 (8.1) | 62.3 (8.0) | 66.1 (7.7) |
| Lumbar spine BMD T-score | −2.14 (0.78) | −2.14 (0.77) | −1.55 (0.96) |
| Total hip BMD T-score | −1.44 (0.71) | −1.42 (0.69) | −1.21 (0.73) |
| One-third BMD T-score | −1.48 (1.21) | −1.48 (1.18) | −1.35 (1.19) |
| Albumin-adjusted calcium, mg/dL | 9.77 (0.37) | 9.77 (0.37) | 9.86 (0.37) |
| Creatinine, mg/dL | 0.76 (0.15) | 0.76 (0.15) | 0.83 (0.16) |
| Subjects who completed, n (%) | 262 (64 %) | 203 (64 %) | 138 (69 %) |
Values are mean (SD) unless indicated otherwise